STOCK TITAN

Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR Dealing

Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Tiziana Life Sciences has disclosed that Gabriele Cerrone, Executive Chairman, acquired 45,000 ordinary shares at 84p each on November 18, 2020. This purchase increased Cerrone's shareholding from 34.029% to 34.052%, just above the 1% threshold under the UK Takeover Code. The acquisition reflects Cerrone's continued confidence in the company's prospects within the biotechnology sector, which focuses on oncology and infectious diseases.

Positive
  • Gabriele Cerrone's increased shareholding indicates strong confidence in Tiziana Life Sciences' future.
Negative
  • None.

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share.

The acquisition takes Mr Cerrone's interests from 34.029% to 34.052% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code).

1.Details of PDMR / person closely associated
a)Name

Gabriele Cerrone
2.Reason for the notification

a)Position / status

Executive Chairman
b)Initial notification /amendment

Initial notification
3.Details of the issuer

a)Name

Tiziana Life Sciences plc
b)LEI

213800CED47HI8PIOB36
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type  of transaction; (iii) each date; and (iv) each place where transactions have  been conducted
a)Description of the financial instrument

Ordinary Shares of 3p each
b)Identification code of the Financial Instrument

ISIN for Tiziana Life Sciences plc: GB00BKWNZY55
c)Nature of the transaction

Market Purchase
d)Price(s) and volume(s)84p

45,000
f)Date of the transaction

18 November 2020
{ "@context": "https://schema.org", "@type": "FAQPage", "name": "Tiziana Life Sciences PLC (\"Tiziana\" or the \"Company\") - PDMR Dealing FAQs", "mainEntity": [ { "@type": "Question", "name": "What was the date of Gabriele Cerrone's share purchase in Tiziana Life Sciences?", "acceptedAnswer": { "@type": "Answer", "text": "Gabriele Cerrone purchased shares on November 18, 2020." } }, { "@type": "Question", "name": "How many shares did Gabriele Cerrone acquire?", "acceptedAnswer": { "@type": "Answer", "text": "He acquired 45,000 ordinary shares." } }, { "@type": "Question", "name": "What was the purchase price of the shares?", "acceptedAnswer": { "@type": "Answer", "text": "The shares were purchased at 84p each." } }, { "@type": "Question", "name": "What is Gabriele Cerrone's new ownership percentage in Tiziana Life Sciences?", "acceptedAnswer": { "@type": "Answer", "text": "Cerrone's ownership increased to 34.052%." } }, { "@type": "Question", "name": "What is the significance of the 1% threshold in the UK Takeover Code?", "acceptedAnswer": { "@type": "Answer", "text": "The 1% threshold is relevant for disclosure of changes in substantial shareholdings." } } ] }

FAQ

What was the date of Gabriele Cerrone's share purchase in Tiziana Life Sciences?

Gabriele Cerrone purchased shares on November 18, 2020.

How many shares did Gabriele Cerrone acquire?

He acquired 45,000 ordinary shares.

What was the purchase price of the shares?

The shares were purchased at 84p each.

What is Gabriele Cerrone's new ownership percentage in Tiziana Life Sciences?

Cerrone's ownership increased to 34.052%.

What is the significance of the 1% threshold in the UK Takeover Code?

The 1% threshold is relevant for disclosure of changes in substantial shareholdings.

Tiziana Life Sciences Ltd. Common Shares

NASDAQ:TLSA

TLSA Rankings

TLSA Latest News

TLSA Stock Data

99.67M
71.31M
35.56%
0.94%
0.23%
Biotechnology
Healthcare
Link
United States of America
London